DOCSLIB.ORG

Role of FGF1, FGF2 and FGF7 in the Development of the Pancreas of Diabetic Hamsters

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of FGF1, FGF2 and FGF7 in the Development of the Pancreas of Diabetic Hamsters Institute of Experimental Morphology and Anthropology with Museum Bulgarian AnatomiCal Society ACta morphologiCa et anthropologiCa, 12 Sofia • 2007 Role of FGF1, FGF2 and FGF7 in the Development of the Pancreas of Diabetic Hamsters M. Inchovska, V. Ogneva, Y. Martinova Institute of Experimental Morphology and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia It has been established that in the early postnatal development after treatemenl with streptozotoCin (STZ) the panCreas has the ability to regenerate B-cells. Little is known about the role of fibroblast growth faCtors (FGFs) in the development of the panCreas. That is why we have investigated the effeCts of FGF1,2 and 7, in vitro, on proliferation and differentiation of the diabetiC hamster panCreatiC epithelial Cells in the early postnatal development. The following methods have been used: Cultivation. H.E. staining, P.A.F. staining and histoautoradiography. Our results have shown that in diabetic hamster panCreases at the age pnd 5 FGF2 aCts as a strong stimulator of duCtal epithelial cell proliferation and new islet formation. Key words: fibroblast growth faCtors, diabetes, panCreatiC cells, proliferative activity. IntroduCtion Fibroblast growth faCtor reCeptor (FGFR) signalling has been impliCated in proCesses of proliferation and differentiation in many organs, inCluding the panCreas [12]. Numerous studies show that impairment of FGFR signalling in panCreatiC p Cells leads to diabetes, indicating that FGFR signalling plays a CruCial role in controlling gluCose homeostasis [1, 7,8,12]. It is well known that the formation of new p Cells in the panCreas is a result of two proCesses: differentiation of duCtal preCursor Cells that further assemble into islets, a proCess also Called noogenesis, and proliferation of preexisting differentiated p Cells [3, 10, 18]. It has been established that the injeCtion of STZ at birth destroys 80% of the p Cells thereby induCing a depletion of panCreatiC insulin stores and a severe hyperglyCemiC state [2, 4, 14]. Various studies demonstrate that P cell regeneration that follows p cell destruCtion after STZ treatment involves both p Cell proliferation and neogenesis [5, 9, 19]. It has not yet been established whether the new P cell masses display insulin secretion ability. Studies in the field of reCovery of panCreatiC islet B cells after STZ treatment in the early postnatal development give us grounds to investigate the effect of FGF1, 2 and 7 on the development of diabetic hamster panCreas in this period. 79 Materials and Methods We induCed experimental diabetes in female hamsters during the first 24 hours after mat­ ing of female and male hamsters by intraperitoneal STZ administration at a dose of 65 mg/ kg. For the study we used only these animals from the litter that had a blood gluCose level above 11 mmol/1. We have studied three groups of diabetic hamsters: 20 hamsters at age pnd 1,20 hamsters at age pnd 5, and 20 hamsters at age pnd 10. Pups were deCapitated, their panCreases were disseCted and Cut into small segments. One or two segments from the isolated panCreases were Cultivated in eaCh well of 96 — well plates. For the preparation of organ Cultures from panCreases we used Iscove‘s medium, supplemented with fetal bovine serum (FBS) and 100 U/ml peniCillin and 100pg/ml streptomyCin. In the three groups of hamsters inCubation medium was additionally supplemented with 4, 10 and 100 ng/1 FGF1, FGF2 and FGF7. Wc had also Control wells in the present experiment in whiCh panCreas segments were not treated with the fibroblast growth faCtors and STZ. The panCreatiC pieCes were inCubated at 37 °C with 5% C 02 for 48 hours. After 48 hours, the medium was supplemented with 3H-thymidine in ConCentration 2 /rCi/ml for 8 hours. Then the panCreatiC segments were Fixed in Bouin's solution for 24 hours, embedded in paraffin, seCtioned and stained with H.E. and PA.F aCCording to routine proCedures. After 14 days of exposure the autoradiographs were stained with haematoxilin — Bomer. The proliferative activity of panCreatiC cells was determined by the labelling index (LI) aCCord­ ing to the formula: LI (%) = number of labelled nuClei / number of Counted nuClei x 100. From every slide of the experimental groups we estimated 200 cells. StatistiCal analysis was made by Student's t-test. The results are expressed as mean perCentage ± S.E. Results The H.E. stained slides have shown well developed duCtal epithelium on the periphery of the slides as well as aCinar cells in the Central part of slides obtained from panCreases of diabetic hamsters at age pnd 1 and treated with FGF1 at a conCentration of 4 ng/1 (Fig. 1). The histoautoradiographiC study showed an inCreased proliferative activity of panCreatiC epithelial cells in the three groups of diabetic hamsters — pnd 1, pnd 5 and pnd 10, and in all ConCentrations of the investigated FGFs. We have observed a large number of prolifer­ ating duCtal cells as well as proliferating Cells around the duCts on slides obtained from panCreases of the diabetic hamsters at age pnd 5 and treated with FGF2 at a ConCentration of 10 ng/1 (Fig. 2). We have also observed proliferating exoCrine cells on slides obtained from panCreases of the diabetic hamsters at age pnd 5 and after treatment with FGF1 at a ConCentration of 4 ng/1. Slides stained with PAF provided additional knowledge about the role of FGFs in the early postnatal development of the panCreas of diabetic hamsters. We have observed insu­ lin - synthesizing cells in the duCtal epithelium on slides obtained from panCreases of the diabetic hamsters at age pnd 5 treated with FGF1 at a ConCentration of 4 ng/1 as well as on slides obtained from panCreases of the diabetiC hamsters at age pnd 10 and treated with FGF1 at a ConCentration of 10 ng/1 (Fig. 3). Insulin-synthesizing cells sCattered throughout the aCinar cells have also been deteCted on slides obtained from panCreases of the diabetic hamsters at age pnd 5 and treated with FGF2 at a ConCentration of 4 ng/1 (Fig. 4). We Could also see insulin - positive islets of Langerhans on slides obtained from panCreases of the diabetiC hamsters at age pnd 5 and treated with FGF1 at a ConCentration of 100 ng/1» (Fig. 5). 80 Fig. 1. DuCtal epithelial Cells in panCreas of diabetiC hamsters atagepnd 1 after treatement with FGF1 at a ConCentration of 4 ng/1 (x 25) Fig. 2. Autoradiograph of diabetiC hamster panCreas at age pnd 5 after treatement with FGF2 at a ConCentration of 10 ng/1 (x 5) 6 Acta morphologica et anthropologiCa, 12 81 Fig. 3. Insulin - synthesizing cells in the duCtal epithelium of diabetiC hamster panCreas at age pnd 5 treated with FGF1 at a ConCentration of 4 ng/1 (x 25) Fig. 4. Insulin - synthesizing cells sCattered throughout the aCinar cells in diabetiC hamster panCreas at age pnd 5 after trealement with FGF2 at a ConCentration of 4 ng/1 (x 25) 82 Fig. 5. Insulin - positive islets of Langerhans in diabetiC hamster panCreas at age pnd 5 after treatement with FGF1 at a ConCentration of 100 ng/1 (x 100) We have determined the proliferative aCtivity of panCreatiC Cells by the labelling index (LI). The Control for experiments for pnd 1 had labelling index 4,2 ± 0,4%, Control for experiments for pnd 5 had labelling index 6 %, Control for experiments for pnd 10 had labelling index 6+ 0,4%. FGF1 has shown the strongest effeCt (18,7 ± 0,6%,p< 0,05 in Comparison with the Control) at age pnd 5 and at a ConCentration of 10 ng/1 and the lowest mitogeniC effect - (7 ± 1,6%) at pnd 1 and at a ConCentration of 100 ng/1. FGF2 has displayed the strongest mitogenic effect (26,2 ± 0,4%, p< 0,01 in Comparison with the Control) at a ConCentration of 10 ng/1 and at age pnd 5 and the lowest (13 ± 0,4%, p< 0,001 in Comparison with the Control) — at a ConCentration of 4 ng/1 and at age pnd 1. FGF7 has shown the strongest mitogenic effect (16,2 ± 0,6%, p< 0,05 in Comparison with the Control) at a ConCentration of 10 ng/1 and at age pnd 5 and the lowest effect (5,5 ± 1,6%) — at a ConCentration of 100 ng/1 and at age pnd 1. The most prominent stimulatory effect (26, 2 ± 0,6 %,p< 0,01 in Comparison with the Control) was registered at a ConCentration of 10 ng/1 of FGF2 and at age pnd 5 and the lowest mitogeniC effeCt — (5,5 ± 1,6%) was registered at a ConCentration of 100 ng/1 FGF7 at age pnd 1. DisCussion It is generally admitted that the proCess of neogenesis mostly takes plaCe during natal and early postnatal development. S t e i n e r et al., Consider that B cells have a poor regenerative activity and that treatment with STZ leads to B Cell destruCtion and irreversible diabetes [16]. Conversely, in rats treated with STZ at birth or at age pnd 2,3 a destruCtion of the B Cell mass causes diabetes followed by a rapid reappearanCe of B cell masses [2,9,14]. 83 While data related to the development the panCreas aCCumulate, little is known about the faCtors that Control the proliferation and differentiation of the B cells in normal and diabetiC animals. It is established that FGF1, FGF2 and FGF7 are among the growth faCtors that are expressed in B cells. That is why the purpose of our study was to establish the effect of these FGFs in the early postnatal development of diabetic hamsters and to get a further insight into the proCess of regeneration of beta cells after treatment with STZ.
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
    cancers Review The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives Maria Francesca Santolla and Marcello Maggiolini * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; [email protected] * Correspondence: [email protected] or [email protected] Received: 8 September 2020; Accepted: 16 October 2020; Published: 18 October 2020 Simple Summary: The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging therapeutic target in breast cancer. Here, we discussed previous studies dealing with FGFR molecular aberrations, the alterations in the FGF/FGFR signaling across the different subtypes of breast cancer, the functional interplay between the FGF/FGFR axis and important components of the breast microenvironment, the therapeutic usefulness of FGF/FGFR inhibitors for the treatment of breast cancer. Abstract: One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer.
    [Show full text]
  • Ep 3217179 A1
    (19) TZZ¥ ___T (11) EP 3 217 179 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.09.2017 Bulletin 2017/37 G01N 33/68 (2006.01) (21) Application number: 17167637.2 (22) Date of filing: 02.10.2013 (84) Designated Contracting States: • LIU, Xinjun AL AT BE BG CH CY CZ DE DK EE ES FI FR GB San Diego, CA 92130 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAUENSTEIN, Scott PL PT RO RS SE SI SK SM TR San Diego, CA 92130 (US) • KIRKLAND, Richard (30) Priority: 05.10.2012 US 201261710491 P San Diego, CA 92111 (US) 17.05.2013 US 201361824959 P (74) Representative: Krishnan, Sri (62) Document number(s) of the earlier application(s) in Nestec S.A. accordance with Art. 76 EPC: Centre de Recherche Nestlé 13779638.9 / 2 904 405 Vers-chez-les-Blanc Case Postale 44 (71) Applicant: Nestec S.A. 1000 Lausanne 26 (CH) 1800 Vevey (CH) Remarks: (72) Inventors: This application was filed on 21-04-2017 as a • SINGH, Sharat divisional application to the application mentioned Rancho Santa Fe, CA 92127 (US) under INID code 62. (54) METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING (57) The present invention provides methods for pre- an individual with a disease such as IBD. Information on dicting the likelihood of mucosal healing in an individual mucosal healing status derived from the use of the with a disease such as inflammatory bowel disease present invention can also aid in optimizing therapy (IBD).
    [Show full text]
  • Mechanism of FGF7 Gene Silencing in Regulating Viability, Apoptosis, Invasion of Retinoblastoma Cell Line HXO-Rb44 and Angiogenesis
    European Review for Medical and Pharmacological Sciences 2020; 24: 3538-3547 Mechanism of FGF7 gene silencing in regulating viability, apoptosis, invasion of retinoblastoma cell line HXO-Rb44 and angiogenesis W.-J. CHEN1, C.-X. SUN2, W. LI3 1Department of Orthopedics Surgery, Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China 2Department of Ophthalmology, Yueyang Huashahengkang Hospital, Yueyang, Hunan Province, China 3Department of Ophthalmology, Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China Abstract. – OBJECTIVE: To explore the mech- Key Words: anism of fibroblast growth factor 7 (FGF7) gene Gene silencing, Retinoblastoma, Apoptosis, Inva- silencing in regulating viability, apoptosis, inva- sion. sion of retinoblastoma (RB) cell line HXO-Rb44 and angiogenesis. MATERIALS AND METHODS: Human normal retinal vascular endothelial cells ACBRI-181 was set as the normal group. The cultured RB cell lines Introduction HXO-Rb44 were divided into three groups: the blank group (without plasmid transfection), nega- Retinoblastoma (RB) is a common primary tive control group (transfection of FGF7 plasmid), intraocular malignant cancer in children that aris- and the si-FGF7 group (transfection of FGF7 siR- NA plasmid). Quantitative Real Time-Polymerase es mainly in the embryonal nuclear layer of the Chain Reaction and Western blot were used to retina. Retinoblastoma is often accompanied by measure the mRNA and protein expression of strabismus and leukocoria in children1. Early di- B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X agnosis and treatment of RB is the key to improve protein (Bax), vascular endothelial growth fac- eye retention rate.
    [Show full text]
  • FGF7 Is a Functional Niche Signal Required for Stimulation of Adult Liver Progenitor Cells That Support Liver Regeneration
    Downloaded from genesdev.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration Hinako M. Takase,1,5,6 Tohru Itoh,1,5,7 Seitaro Ino,1 Ting Wang,2 Takehiko Koji,3 Shizuo Akira,4 Yasuhiro Takikawa,2 and Atsushi Miyajima1 1Laboratory of Cell Growth and Differentiation, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo 113-0032, Japan; 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 020-8505, Japan; 3Department of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; 4Laboratory of Host Defense, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan The liver is a unique organ with a remarkably high potential to regenerate upon injuries. In severely damaged livers where hepatocyte proliferation is impaired, facultative liver progenitor cells (LPCs) proliferate and are assumed to contribute to regeneration. An expansion of LPCs is often observed in patients with various types of liver diseases. However, the underlying mechanism of LPC activation still remains largely unknown. Here we show that a member of the fibroblast growth factor (FGF) family, FGF7, is a critical regulator of LPCs. Its expression was induced concomitantly with LPC response in the liver of mouse models as well as in the serum of patients with acute liver failure. Fgf7-deficient mice exhibited markedly depressed LPC expansion and higher mortality upon toxin-induced hepatic injury. Transgenic expression of FGF7 in vivo led to the induction of cells with characteristics of LPCs and ameliorated hepatic dysfunction.
    [Show full text]
  • Mesenchymal Stem Cells: Mechanisms of Potential Therapeutic Benefi T in ARDS and Sepsis
    Review Mesenchymal stem cells: mechanisms of potential therapeutic benefi t in ARDS and sepsis James Walter, Lorraine B Ware, Michael A Matthay Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic eff ects in preclinical Lancet Respir Med 2014 models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the Published Online ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic October 28, 2014 eff ects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of http://dx.doi.org/10.1016/ S2213-2600(14)70217-6 these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. Departments of Medicine and This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine Anaesthesia, Cardiovascular eff ects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise Research Institute, University ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years. of California, San Francisco, CA, USA (J Walter MD, M A Matthay MD); and Division 12 Introduction lifespan in vivo. Finally, once isolated from host tissue, of Allergy, Pulmonary and Advances in supportive care have markedly improved MSCs can be expanded rapidly ex vivo, which enables Critical Care Medicine, survival for
    [Show full text]
  • Derived Keratinocyte Growth Factor and Epithelial Transforming Growth Factor in Immune- Mediated Crypt Cell Hyperplasia
    Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune- mediated crypt cell hyperplasia. M Bajaj-Elliott, … , N C Wathen, T T MacDonald J Clin Invest. 1998;102(8):1473-1480. https://doi.org/10.1172/JCI2792. Research Article Immune reactions in the gut are associated with increased epithelial cell proliferation. Here we have studied the role of keratinocyte growth factor (KGF; FGF7) and transforming growth factor-alpha (TGF-alpha) in the epithelial cell hyperplasia seen in explants of fetal human small intestine after activation of lamina propria T cells with the superantigen Staphylococcus aureus enterotoxin B (SEB). After the addition of SEB to the explants there is a 10-fold increase in KGF mRNA by 72 h of culture. KGF transcripts were abundant in the lamina propria using in situ hybridization and the culture supernatants contained elevated amounts of KGF protein. SEB had no direct effect on KGF mRNA and protein production by cultured lamina propria mesenchymal cells, but both were upregulated by TNF-alpha. Accompanying the increase in KGF there was also an increase in TGF-alpha precursor proteins in the culture supernatants and the phosphorylated form of the EGFR receptor was also detected in the tissue. Increased TGF-alpha precursor proteins were also detected in the supernatants of control explants stimulated with KGF alone. The direct addition of KGF and TGF-alpha enhanced epithelial cell proliferation and antibodies against KGF and TGF-alpha partially inhibited SEB-induced crypt hyperplasia. These results suggest molecular cross-talk between the KGF/KGFR and the TGF-alpha/EGFR in immune-mediated crypt cell hyperplasia.
    [Show full text]
  • The MAPKERK-1,2 Pathway Integrates Distinct and Antagonistic Signals from TGF Alpha and FGF7 in Morphogenesis of Mouse Mammary Epithelium
    Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title The MAPKERK-1,2 pathway integrates distinct and antagonistic signals from TGF alpha and FGF7 in morphogenesis of mouse mammary epithelium Permalink https://escholarship.org/uc/item/7075z967 Author Fata, Jimmie E Publication Date 2007-03-16 DOI 10.1016/j.ydbio.2007.03.013 Peer reviewed eScholarship.org Powered by the California Digital Library University of California The MAPKERK-1,2 pathway integrates distinct and antagonistic signals from TGFα and FGF7 in morphogenesis of mouse mammary epithelium Jimmie E. Fata a* Hidetoshi Mori a, Andrew J. Ewald b, Hui Zhang a, Evelyn Yao a, Zena Werb b, Mina J. Bissell a* a Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA b Department of Anatomy, University of California, San Francisco, CA 94143, USA *Corresponding Authors: Jimmie Fata Life Science Division, Lawrence Berkeley National Laboratory One Cyclotron Road, Berkeley, CA 94720, USA e-mail: [email protected] Mina Bissell Life Science Division, Lawrence Berkeley National Laboratory One Cyclotron Road, MS 977R225A, Berkeley, CA 94720, USA e-mail: [email protected] Tel: +1 510 486 4365 Fax: +1 510 486 5586 LBNL/DOE funding & contract number: DE-AC02-05CH11231 Abstract Transforming growth factor-α (TGFα) and fibroblast growth factor-7 (FGF7) exhibit distinct expression patterns in the mammary gland. Both factors signal through mitogen- activated kinase/extracellular regulated kinase-1,2 (MAPKERK1,2); however, their unique and/or combined contributions to mammary morphogenesis have not been examined. In ex vivo mammary explants, we show that a sustained activation of MAPKERK1,2 for 1 h, induced by TGFα, was necessary and sufficient to initiate branching morphogenesis, whereas a transient activation (15 min) of MAPKERK1,2, induced by FGF7, led to growth without branching.
    [Show full text]
  • Increased Keratinocyte Proliferation by JUN-Dependent Expression of PTN and SDF-1 in Fibroblasts
    Research Article 1981 Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1 in fibroblasts Lore Florin1, Nicole Maas-Szabowski2, Sabine Werner3, Axel Szabowski1 and Peter Angel1,* 1Division of Signal Transduction and Growth Control, and 2Division of Differentiation and Carcinogenesis, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany 3Institute of Cell Biology, ETH Zürich, Hoenggerberg, 8093 Zürich, Switzerland *Author for correspondence (e-mail: [email protected]) Accepted 3 February 2005 Journal of Cell Science 118, 1981-1989 Published by The Company of Biologists 2005 doi:10.1242/jcs.02303 Summary In skin, fibroblasts of the connective tissue play a decisive on primary human keratinocytes. Moreover, SDF-1- role in epidermal homeostasis and repair by contributing induced keratinocyte proliferation could be specifically to the regulation of keratinocyte proliferation and inhibited by neutralizing antibodies against SDF-1 or its differentiation. The AP-1 transcription factor subunit JUN receptor, CXCR4. Consistent with its role in promoting plays a crucial role in this mesenchymal-epithelial interplay keratinocyte growth, PTN was upregulated during by regulating the expression of two critical paracrine- cutaneous wound healing in vivo. Interestingly, co- acting cytokines, keratinocyte growth factor (KGF) and cultivation with keratinocytes stimulated PTN expression granulocyte-macrophage colony-stimulating factor (GM- but repressed SDF-1 production in fibroblasts, CSF). We have performed gene expression profiling of wild- demonstrating the complexity of the paracrine regulatory type and Jun–/– mouse embryonic fibroblasts to identify cytokine networks that control skin homeostasis and additional players involved in this complex network, and regeneration. have found pleiotrophin (PTN) and the stromal cell-derived factor 1 (SDF-1) as novel JUN-regulated factors.
    [Show full text]
  • Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
    cells Review Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis Jinglin Zhang 1,2,3, Patrick M. K. Tang 1, Yuhang Zhou 1,2,3, Alfred S. L. Cheng 4, Jun Yu 2,5, Wei Kang 1,2,3,* and Ka Fai To 1,2,3,* 1 Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; [email protected] (J.Z.); [email protected] (P.M.K.T.); [email protected] (Y.Z.) 2 Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; [email protected] 3 Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China 4 School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China; [email protected] 5 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China * Correspondence: [email protected] (W.K.); [email protected] (K.F.T.); Tel.: +(852)-3505-1505 (W.K.); Fax: +(852)-2649-7286 (W.K.) Received: 23 May 2019; Accepted: 24 June 2019; Published: 25 June 2019 Abstract: Gastric cancer (GC) is one of the most wide-spread malignancies in the world. The oncogenic role of signaling of fibroblast growing factors (FGFs) and their receptors (FGFRs) in gastric tumorigenesis has been gradually elucidated by recent studies. The expression pattern and clinical correlations of FGF and FGFR family members have been comprehensively delineated.
    [Show full text]
  • Review Peptide Gene Expression in Gastrointestinal Mucosal
    286 Gut 2000;46:286–292 Review Gut: first published as 10.1136/gut.46.2.286 on 1 February 2000. Downloaded from Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy? Summary repair by stimulating the migration of surviving cells from Many genes, some encoding peptides, are upregulated after the edge of the damaged region over the denuded area, a mucosal damage in the gastrointestinal mucosa: we have process known as epithelial restitution. Exogenous looked for an ordered sequence in the expression of genes TFF2/SP increases cell migration in in vitro models of cell such as c-fos,c-jun, egr-1, Sp-1, epidermal growth factor, wounding34and also acts as a cytoprotective agent in rats transforming growth factors á and â, trefoil peptides, epi- treated with indomethacin. Thus TFF2/SP has been dermal growth factor receptor, hepatocyte growth factor, proposed as a rapid response peptide.5 c-met, fibroblast growth factor, platelet derived growth fac- Epidermal growth factor (EGF) is an 53 amino acid tor, and vascular endothelial growth factor. All of these peptide found in the salivary glands and the duodenal gene products play an important reparative role, assisting Brunner’s glands. It is one of the most extensively studied appropriate healing of the damaged mucosa. There does peptides in healing of gastric mucosal lesions,6–9 but its indeed seem to be a temporal sequence in this gene exact function in human physiology is not yet fully defined. expression, but there is a certain degree of redundancy EGF is a potent stimulant of growth and repair when within the system, both in terms of receptor binding and infused systemically, inhibits gastric acid secretion, and has the function of the gene products.
    [Show full text]